Aspergillus-specific IgG Assays for the Diagnosis of Chronic Pulmonary Aspergillosis (CPA)-Multicenter Study


Chinese PLA General Hospital (301 Hospital)




Chronic Pulmonary Aspergillosis

Study type


Funder types




Details and patient eligibility


Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA)

Full description

chronic pulmonary aspergillosis (CPA) is one of the most refractory pulmonary infectious diseases, and the incidence is increased rapidly in recent years. Serum detection of Aspergillus-specific IgG is considered to be the most reliable method for diagnosing CPA, however, there is no formal report on the appropriate cut-off value for Aspergillus-specific IgG assay in Chinese patients. This study aimed to establish the datum. Besides aspergillus-specific IgG, there are two other specific antibodies IgM and IgA. IgM is associated with the acute phase of an infection and IgA is associated with mucosal immunity. Their diagnostic values in CPA are still not clear. Meanwhile, whether detection of antibody levels in bronchoalveolar lavage fluid (BALF) could be useful in diagnosis of CPA has not been investigated. In this study, the serum and BALF levels of IgG, IgM and IgA would be detected simultaneously by the commercial available kits. The investigators will establish the cut-off values of three antibodies by proven CPA patients and negative controls. Then, the cut-off values will be assessed in participants who have a suspected CPA, and the sensitivity, specificity, positive and negative predict value of the antibodies assays will be compared with that of standard diagnostic methods. After performing the above diagnostic tests, CPA could be diagnosed more accurately and rapidly, so that the antifungal therapy could be evaluated more correctly and timely.


560 estimated patients




18 to 85 years old


Accepts Healthy Volunteers

Inclusion criteria

18 years to 85 years Lesions presented as cavity, nodule,mass or "destroyed lung" caused by fibrosis in CT imaging

Exclusion criteria

seriously immunocompromised patients

  • Recent history of neutropenia (<0.5 × 109neutrophils/L [<500 neutrophils/mm3] for>10 days) temporally related to the onset of fungal disease
  • Receipt of an allogeneic stem cell transplant
  • Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a mean minimum dose of 0.3 mg/kg/day of prednisone equivalent for >3 weeks
  • Treatment with other recognized T cell immunosuppressants, such as cyclosporine, TNF-a blockers, specific monoclonal antibodies (such as alemtuzumab), or nucleoside analogues during the past 90 days
  • Inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency)
  • antifungal drug use within 3 months of screening
  • dropout
  • Pregnancy or lactation
  • no inform consent

Trial contacts and locations



Central trial contact

xiuqing ma, Doctor

Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems